Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
| Autor: | Song, Yuqin, Malpica, Luis, Cai, Qingqing, Zhao, Weili, Zhou, Keshu, Wu, Jianqiu, Zhang, Huilai, Mehta-Shah, Neha, Ding, Kaiyang, Liu, Yao, Li, Zengjun, Zhang, Liling, Zheng, Meifang, Jin, Jie, Yang, Haiyan, Shuang, Yuerong, Yoon, Dok Hyun, Gao, Sujun, Li, Wenyu, Zhai, Zhimin, Zou, Liqun, Xi, Yaming, Koh, Youngil, Li, Fei, Prince, Miles, Zhou, Hui, Lin, Lie, Liu, Hui, Allen, Pamela, Roncolato, Fernando, Yang, Zhenfan, Kim, Won-Seog, Zhu, Jun * |
|---|---|
| Zdroj: | In The Lancet Oncology January 2024 25(1):117-125 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|